135 related articles for article (PubMed ID: 8536900)
1. A prospective, double-blind trial of somatostatin analog (octreotide) versus glucagon for the inhibition of small intestinal motility during endoscopic retrograde cholangiopancreatography.
Van Dam J; Catalano MF; Ferguson DR; Barnes DS; Zuccaro G; Sivak MV
Gastrointest Endosc; 1995 Oct; 42(4):321-4. PubMed ID: 8536900
[TBL] [Abstract][Full Text] [Related]
2. A prospective, double-blind trial of L-hyoscyamine versus glucagon for the inhibition of small intestinal motility during ERCP.
Lahoti S; Catalano MF; Geenen JE; Hogan WJ
Gastrointest Endosc; 1997 Aug; 46(2):139-42. PubMed ID: 9283863
[TBL] [Abstract][Full Text] [Related]
3. Sublingual L-hyoscyamine for duodenal antimotility during ERCP: a prospective randomized double-blinded study.
Lynch CR; Khandekar S; Lynch SM; Disario JA
Gastrointest Endosc; 2007 Oct; 66(4):748-52. PubMed ID: 17905018
[TBL] [Abstract][Full Text] [Related]
4. The effects of somatostatin and octreotide on the human sphincter of Oddi.
Velõsy B; Madácsy L; Szepes A; Pávics L; Csernay L; Lonovics J
Eur J Gastroenterol Hepatol; 1999 Aug; 11(8):897-901. PubMed ID: 10514124
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acts on anorectal physiology: a dynamic study in healthy subjects.
Siproudhis L; Bellissant E; Juguet F; Allain H; Bretagne JF; Gosselin M
Clin Pharmacol Ther; 1998 Oct; 64(4):424-32. PubMed ID: 9797799
[TBL] [Abstract][Full Text] [Related]
6. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Soudah HC; Hasler WL; Owyang C
N Engl J Med; 1991 Nov; 325(21):1461-7. PubMed ID: 1944424
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography.
Yamamoto N; Nakai Y; Sasahira N; Hirano K; Tsujino T; Isayama H; Komatsu Y; Tada M; Yoshida H; Kawabe T; Hiki N; Kaminishi M; Kurosaka H; Omata M
J Gastroenterol Hepatol; 2006 Sep; 21(9):1394-8. PubMed ID: 16911682
[TBL] [Abstract][Full Text] [Related]
8. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography.
Duvnjak M; Supanc V; Simicević VN; Hrabar D; Troskot B; Smircić-Duvnjak L; Bekavac-Beslin M
Acta Med Croatica; 1999; 53(3):115-8. PubMed ID: 10705631
[TBL] [Abstract][Full Text] [Related]
9. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?
Binmoeller KF; Harris AG; Dumas R; Grimaldi C; Delmont JP
Gut; 1992 Aug; 33(8):1129-33. PubMed ID: 1383099
[TBL] [Abstract][Full Text] [Related]
10. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome.
Richards WO; Geer R; O'Dorisio TM; Robarts T; Parish KL; Rice D; Woltering G; Abumrad NN
J Surg Res; 1990 Dec; 49(6):483-7. PubMed ID: 2263084
[TBL] [Abstract][Full Text] [Related]
11. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
Poon RT; Fan ST
JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
[TBL] [Abstract][Full Text] [Related]
12. [Effects of somatostatin and its analogue on canine sphincter of Oddi motility].
Wang C; Lu X; Chen Y
Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):621-3. PubMed ID: 11798831
[TBL] [Abstract][Full Text] [Related]
13. Octreotide relaxes the hypertensive sphincter of Oddi: pathophysiological and therapeutic implications.
Fazel A; Li SC; Burton FR
Am J Gastroenterol; 2002 Mar; 97(3):612-6. PubMed ID: 11922555
[TBL] [Abstract][Full Text] [Related]
14. Effects of octreotide on manometric variables in patients with neuropathic abnormalities of the small bowel.
Bassotti G; Germani U; Calcara C; Spinozzi F; Roselli P; Morelli A
Dig Dis Sci; 1997 Aug; 42(8):1634-9. PubMed ID: 9286228
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
[TBL] [Abstract][Full Text] [Related]
16. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.
Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST
Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
Sternlieb JM; Aronchick CA; Retig JN; Dabezies M; Saunders F; Goosenberg E; Infantolino A; Ionna S; Maislin G; Wright SH
Am J Gastroenterol; 1992 Nov; 87(11):1561-6. PubMed ID: 1279967
[TBL] [Abstract][Full Text] [Related]
18. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats.
Nieuwenhuijs VB; van Duijvenbode-Beumer H; Verheem A; Visser MR; Verhoef J; Gooszen HG; Akkermans LM
Eur J Clin Invest; 1999 Jan; 29(1):33-40. PubMed ID: 10092986
[TBL] [Abstract][Full Text] [Related]
19. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis.
Kisli E; Baser M; Aydin M; Guler O
Hepatogastroenterology; 2007; 54(73):250-3. PubMed ID: 17419271
[TBL] [Abstract][Full Text] [Related]
20. Factors that affect the variability in heart rate during endoscopic retrograde cholangiopancreatography.
Christensen M; Reinert R; Rasmussen V; Schulze S; Rosenberg J
Eur J Surg; 2002; 168(10):546-51. PubMed ID: 12666694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
